Another ICI, such as Durvalumab (anti-PD-L1) is approved as a maintenance treatment for patients with inoperable stage 3 NSCLC whose disease had not progressed upon concurrent platinum-based chemoradiotherapy [94]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.